ÂÜÀòÂÒÂ×

Christine Schuberth-Wagner serves as Chief Scientific Officer at CatalYm. She joined the company in November 2018 with more than 10 years of experience in drug discovery and non-clinical development of immunomodulatory drugs in the immuno-oncology space. She has established a track record as a successful leader and entrepreneur in the biotech industry. Prior to joining CatalYm, Christine co-founded Rigontec in 2014 where she led the company’s discovery and non-clinical development activities as Senior Vice President, Research. Her discoveries on the first-in-class RNA-based innate immune receptor agonist RGT100, built the foundation for the initiation of a Phase 1 clinical trial as well as the successful acquisition of Rigontec by MSD (known as Merck & Co. in North America) in late 2017. Christine holds a PhD in Molecular Biomedicine from the University of Bonn and an MBA from the University of Potsdam.